Intelligence coverage: 60%

Basic profile, financials, and market data are shown below. Deep research is building in the background.

IONS

IONIS PHARMACEUTICALS INC

Healthcare · Pharmaceutical Preparations

$45.89Sep 29, 2026

AI confidence 63% · prior close shown (market closed)

Investment Snapshot

Weak evidence · 1 source

Why it matters

IONIS PHARMACEUTICALS INC shows decelerating business momentum based on AlphaOS pipeline evidence.

Why it matters: Revenue -41% YoY in Q2 FY2026.

TrajectoryDecelerating

3 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

  • Revenue -41% YoY in Q2 FY2026

Pipeline evidence · 0d ago

IONS's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on IONS.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q2 2026

Full IONS earnings analysis

Reported figures for IONIS PHARMACEUTICALS INC — research only, not investment advice.

Revenue YoY
-40.7%
EPS YoY
-198.6%

Latest Intelligence

Updated

What happened recently for IONIS PHARMACEUTICALS INC (IONS) — events, not interpretation.

Event
Reported Q2 2026 revenue -41% YoY.
Also
Last session September 29, 2026 at $45.89.
Source
Q2 2026 earnings

Research & analysis only — not investment advice.

Building company intelligence…

IONIS PHARMACEUTICALS INC (IONS)

Healthcare · Pharmaceutical Preparations

Investment Snapshot above is the primary AlphaOS analysis for IONIS PHARMACEUTICALS INC — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:
Healthcare
Market cap:
$7.63B
Revenue:
$267.95M

IONS earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow IONIS PHARMACEUTICALS INC through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Connected companies and research pages from the AlphaOS knowledge graph.

Structured stock intelligence for companies connected to this research.